KROS Stock Forecast 2025-2026
Distance to KROS Price Targets
KROS Price Momentum
10 Quality Stocks Worth Considering Now
Researching Keros (KROS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on KROS and similar high-potential opportunities.
Latest KROS Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, KROS has a bullish consensus with a median price target of $29.50 (ranging from $15.00 to $76.00). The overall analyst rating is Strong Buy (8.2/10). Currently trading at $14.42, the median forecast implies a 104.6% upside. This outlook is supported by 8 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Greg Harrison at B of A Securities, projecting a 427.0% upside. Conversely, the most conservative target is provided by Yun Zhong at Wedbush, suggesting a 4.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KROS Analyst Ratings
KROS Price Target Range
Latest KROS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KROS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $25.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $40.00 |
| Apr 1, 2025 | Wedbush | Yun Zhong | Neutral | Reiterates | $15.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $40.00 |
| Feb 27, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $26.00 |
| Jan 21, 2025 | Cantor Fitzgerald | Prakhar Agrawal | Neutral | Downgrade | $0.00 |
| Jan 17, 2025 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $15.00 |
| Jan 17, 2025 | Guggenheim | Vamil Divan | Neutral | Reiterates | $0.00 |
| Jan 17, 2025 | Wedbush | Andreas Argyrides | Neutral | Downgrade | $15.00 |
| Jan 16, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Maintains | $23.00 |
| Jan 16, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $41.00 |
| Dec 23, 2024 | Truist Securities | Buy | Maintains | $0.00 | |
| Dec 16, 2024 | Oppenheimer | Andreas Argyrides | Outperform | Maintains | $63.00 |
| Dec 16, 2024 | Guggenheim | Vamil Divan | Neutral | Downgrade | $0.00 |
| Dec 13, 2024 | Wells Fargo | Overweight | Maintains | $0.00 | |
| Dec 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $47.00 |
| Dec 13, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $44.00 |
| Dec 12, 2024 | BTIG | Julian Harrison | Neutral | Downgrade | $0.00 |
| Dec 12, 2024 | TD Cowen | Tyler Van Buren | Hold | Downgrade | $0.00 |
| Dec 12, 2024 | William Blair | Matt Phipps | Market Perform | Downgrade | $0.00 |
Keros Therapeutics Inc. (KROS) Competitors
The following stocks are similar to Keros based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Keros Therapeutics Inc. (KROS) Financial Data
Keros Therapeutics Inc. has a market capitalization of $580.04M with a P/E ratio of 0.0x. The company generates $3.55M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +2,027.3% quarter-over-quarter, while maintaining an operating margin of -1,750.6% and return on equity of -41.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Keros Therapeutics Inc. (KROS) Business Model
About Keros Therapeutics Inc.
Develops innovative treatments for serious disorders.
Keros Therapeutics operates as a biopharmaceutical company focused on discovering and commercializing therapies for hematological and musculoskeletal disorders. It generates revenue by advancing its drug candidates through research and clinical trials, ultimately aiming for regulatory approval and market entry to meet significant medical needs.
The company emphasizes targeting the TGF-beta family of proteins, which are crucial for cellular growth and development. Keros has a strong pipeline geared towards treating conditions like anemia and muscle diseases, contributing to advancements in personalized medicine within the healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
169
CEO
Dr. Jasbir S. Seehra Ph.D.
Country
United States
IPO Year
2020
Website
www.kerostx.comKeros Therapeutics Inc. (KROS) Latest News & Analysis
Latest News
Keros Therapeutics adopts 'poison pill' plan
14 days agoKeros Therapeutics' board has approved a stockholder rights plan, or "poison pill," to address rapid stock accumulation by certain investors.
Keros Therapeutics' "poison pill" signals potential takeover defense, which can affect stock value and investor sentiment amidst aggressive buying activity.
U.S. stocks declined mid-session, with the Dow Jones index falling over 4% on Thursday.
A significant drop in the Dow Jones indicates market volatility, potentially signaling economic concerns, influencing investor sentiment and future trading strategies.
Keros Therapeutics, Inc. has begun a formal review of strategic alternatives, including the potential sale of the company, as announced by its board of directors.
Keros Therapeutics' strategic review, including a potential sale, could impact its valuation and stock performance, signaling possible shifts in company direction or value realization for shareholders.
Keros Therapeutics (Nasdaq: KROS) is initiating a review of strategic alternatives to maximize stockholder value, including potential sale, pipeline investment, or capital return.
Keros Therapeutics is evaluating strategic alternatives, which could lead to a sale or partnership. This may significantly impact stock value and investor returns.
The stock surged 18.5% following Keros' announcement of a strategic review process that may lead to a potential sale of the business.
The 18.5% stock rally indicates increased investor confidence in potential value realization through strategic options, including a sale, which could enhance returns.
Keros Therapeutics announces initial topline results from the Phase 1 trial of KER-065 in healthy volunteers, focusing on TGF-ß signaling disorders. Results cover the multiple ascending dose period.
Positive topline results from Keros Therapeutics' Phase 1 trial may boost investor confidence in KER-065's potential, impacting stock performance and future funding opportunities.
Frequently Asked Questions About KROS Stock
What is Keros Therapeutics Inc.'s (KROS) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Keros Therapeutics Inc. (KROS) has a median price target of $29.50. The highest price target is $76.00 and the lowest is $15.00.
Is KROS stock a good investment in 2025?
According to current analyst ratings, KROS has 8 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KROS stock?
Wall Street analysts predict KROS stock could reach $29.50 in the next 12 months. This represents a 104.6% increase from the current price of $14.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Keros Therapeutics Inc.'s business model?
Keros Therapeutics operates as a biopharmaceutical company focused on discovering and commercializing therapies for hematological and musculoskeletal disorders. It generates revenue by advancing its drug candidates through research and clinical trials, ultimately aiming for regulatory approval and market entry to meet significant medical needs.
What is the highest forecasted price for KROS Keros Therapeutics Inc.?
The highest price target for KROS is $76.00 from Greg Harrison at B of A Securities, which represents a 427.0% increase from the current price of $14.42.
What is the lowest forecasted price for KROS Keros Therapeutics Inc.?
The lowest price target for KROS is $15.00 from Yun Zhong at Wedbush, which represents a 4.0% increase from the current price of $14.42.
What is the overall KROS consensus from analysts for Keros Therapeutics Inc.?
The overall analyst consensus for KROS is bullish. Out of 13 Wall Street analysts, 8 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $29.50.
How accurate are KROS stock price projections?
Stock price projections, including those for Keros Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.